AB2 Bio Ltd.   Report issue

For profit Phase 3
Founded: Ecublens Switzerland (2010)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2015
NCT02398435
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

AB2 Bio Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

tadekinig alfa (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Juvenile (Phase 2)

Genetic Diseases, X-Linked (Phase 3)

Lymphoproliferative Disorders (Phase 3)

Still's Disease, Adult-Onset (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1